Global Nasopharyngeal Cancer Market Size study & Forecast, by Therapy (Chemotherapy, Immunotherapy, Radiation Therapy, and Others), by End-User (Hospitals and Clinics, Ambulatory Surgery Centers, and Other End-Users), and Regional Analysis, 2022-2029

Global Nasopharyngeal Cancer Market Size study & Forecast, by Therapy (Chemotherapy, Immunotherapy, Radiation Therapy, and Others), by End-User (Hospitals and Clinics, Ambulatory Surgery Centers, and Other End-Users), and Regional Analysis, 2022-2029

The global Nasopharyngeal Cancer Market is valued at approximately USD XX billion in 2021 and is anticipated to grow with a healthy growth rate of more than XX % over the forecast period 2022-2029. Nasopharyngeal Cancer is a head and neck cancer that possesses a risk of infection than other patients. It is a disease in which malignant cancer cells are formed in the tissues of the nasopharynx. The Nasopharyngeal Cancer market is expanding because of factors such as the rising prevalence of cancer diseases and increasing awareness towards diagnosis and treatment.

According to World Cancer Research Fund International (WCRF) data updated in 2022, NPC is the 22nd most common cancer in the world, ranking 22nd among cancers in women and 18th among cancers in men. According to the WCRF, approximately 133,000 new NPC cases will be diagnosed globally in 2020. Whereas rising government spending on public healthcare and growing clinical trials & cancer research activities create lucrative opportunities for the market. However, higher treatment costs hamper the market growth throughout the forecast period of 2022-2029.

The key regions considered for the Global Nasopharyngeal Cancer Market study include Asia Pacific, North America, Europe, Latin America, and the Rest of the World. Asia Pacific dominated the market in terms of revenue, owing to the increasing research and development expenditure, and growing product approvals associated with clinical trials. Whereas the Asia Pacific is expected to grow with the highest CAGR during the forecast period, owing to factors such as the increasing prevalence of nasopharyngeal cancer and strategic initiatives by market players in the forecast period

Major market players included in this report are:
Biocon Limited
Bristol Myers Squibb Company
Cyclacel Pharmaceuticals
F. Hoffman La-Roche Ltd
Merck & Co., Inc.
Novartis AG
Pfizer, Inc.
GSK plc.
Sanofi
Theravectys SA

Recent Developments in the Market:
 In February 2022, In Kolkata, India, KMC clinics began cancer screening, including nasopharyngeal cancer under the head and neck division. The screening program was developed in partnership with the Indian Medical Association (IMA), the Indian Dental Association (IDA), and Medica Super specialty Hospital. It is expected to be carried out at all 16 KMC centers
 In January 2022, The Wistar Institute initiated a phase 2 trial to investigate the safety and efficacy of the oral inhibitor VK-2019 in patients with advanced Epstein-Barr Virus-positive nasopharyngeal carcinoma, a rare type of head and neck cancer, and lymphoma. Stanford University School of Medicine researchers are leading the trial.

Global Nasopharyngeal Cancer Market Report Scope:
Historical Data 2019-2020-2021
Base Year for Estimation 2021
Forecast period 2022-2029
Report Coverage Revenue forecast, Company Ranking, Competitive Landscape, Growth factors, and Trends
Segments Covered Therapy, End-user, Region
Regional Scope North America; Europe; Asia Pacific; Latin America; Rest of the World
Customization Scope Free report customization (equivalent up to 8 analyst’s working hours) with purchase. Addition or alteration to country, regional & segment scope*

The objective of the study is to define market sizes of different segments & countries in recent years and to forecast the values to the coming years. The report is designed to incorporate both qualitative and quantitative aspects of the industry within countries involved in the study.

The report also caters detailed information about the crucial aspects such as driving factors & challenges which will define the future growth of the market. Additionally, it also incorporates potential opportunities in micro markets for stakeholders to invest along with the detailed analysis of competitive landscape and product offerings of key players.

The detailed segments and sub-segment of the market are explained below:

By Therapy:
Chemotherapy
Immunotherapy
Radiation Therapy
Others

By End-user:
Hospitals and Clinics
Ambulatory Surgery Centers
Other End-users

By Region:
North America
U.S.
Canada
Europe
UK
Germany
France
Spain
Italy
ROE
Asia Pacific
China
India
Japan
Australia
South Korea
RoAPAC
Latin America
Brazil
Mexico
RoLA
Rest of the World

Companies Mentioned

Biocon Limited
Bristol Myers Squibb Company
Cyclacel Pharmaceuticals
F. Hoffman La-Roche Ltd
Merck & Co., Inc.
Novartis AG
Pfizer, Inc.
GSK plc.
Sanofi
Theravectys SA

Please note:The single user license is non-downloadable and non-printable. Global Site license allows these actions.